Cholangiocarcinoma Market Size was USD 786.1 million in 2021

The Cholangiocarcinoma Market is expected to show positive growth attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.

The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, Cholangiocarcinoma market share of the individual therapies, current and forecasted Cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Cholangiocarcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Cholangiocarcinoma market.

Key takeaways from the Cholangiocarcinoma Market Report
• The increase in Market Size is a direct consequence of increasing incident population of Cholangiocarcinoma, an increase in investment in the R&D of drugs leading to a rich pipeline etc. in the 7MM
• According to Sinn et al. (2021), the incidence rate of iCCA was found to be 1.6 and 2.8 per 100,000 in women and men, respectively, whereas the incidence rate of eCCA was found to be 1.8 and 2.9 per 100,000 in women and men, respectively.
• As per DelveInsight analysts, the total Cholangiocarcinoma incident population in the US was estimated to be 10,034 in 2021.
• Cholangiocarcinoma Market Companies included Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutical, Bayer, Loxo Oncology/Bayer, Zymeworks/BeiGene, TArtificial Intelligenceho Oncology, Merck/GlaxoSmithKline, EisArtificial Intelligence, and several others.
• Cholangiocarcinoma Market Therapies included Copanlisib (BAY 80-6946), E7090, Bintrafusp alfa (GSK4045154; M7824), Futibatinib (TAS-120), ZW25, Larotrectinib, Regorafenib, Derazantinib, Melphalan/HDS, and several others.

Download Sample of the Cholangiocarcinoma Market Report- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cholangiocarcinoma Overview
Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation. The major function of the bile duct is to move a fluid called bile from the liver and gallbladder to the small intestine, where it helps digest the fats in food. The causes of the abnormal proliferation in the bile ducts' epithelial cells leading to tumors are unknown and most cases occur sporadically.

The cause-and-effect relationship between the molecular alterations and the transformation of the healthy biliary epithelium into an invasive malignancy, as well as our knowledge of the interactions between the various signaling pathways and components that produce the cancer cell phenotypes, are still unknown despite the significant progress that has been made in molecularly profiling BTC. The successful advancement of translational research in this subject is incredibly challenging due to its scarcity and the challenge of getting acceptable diagnostic samples.

Cholangiocarcinoma Epidemiology Insights
According to the study by Banales et al. (2016), a progressive increase in iCCA incidence worldwide was reported up to the end of the past century, reaching a plateau in the past 10 years. By contrast, the incidences of both pCCA and dCCA seem to be decreasing. The incidence of Cholangiocarcinoma in the US was reported to be 1.67 per 100,000 for the time period of 2003-2009. This incidence is expected to increase and the incident population of Cholangiocarcinoma in the US is expected to increase and reach around 8,000 cases per year in 2018 and further increase to reach around 10,000 cases per year in 2021, according to the Cholangiocarcinoma Foundation (2022).

Cholangiocarcinoma Epidemiology Segmentation in the 7MM
• Total Cholangiocarcinoma diagnosed-incidence cases
• Total Cholangiocarcinoma age-specific cases
• Total Cholangiocarcinoma mutation-specific cases
• Total Cholangiocarcinoma type-specific cases
• Total Cholangiocarcinoma stage-specific Cases
• Total Cholangiocarcinoma treated Cases

Cholangiocarcinoma Market Landscape
Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. Bile ducts connect your liver to your gallbladder and to your small intestine. Cholangiocarcinoma (CCA). Cholangiocarcinoma (CCA) tumors can arise from anywhere in the biliary tract and may be difficult to identify based on histopathologic analysis alone. CCA is further divided into intra-hepatic CCA, perihilar (Klatskin's tumor), and distal CCA.

Cholangiocarcinoma Treatment
The complexity of cholangiocarcinoma, clinical management should be planned as part of a multidisciplinary team considering patient-related factors (eg, ECOG performance status, comorbidities, preferences), disease-related variables (eg, tumor stage, vascular involvement, presence of distant metastases), and avArtificial Intelligencelability of specialist expertise (high-volume centers are associated with a lower mortality rate for major liver resections). Surgery is the cornerstone of curative therapy and the approach depends on the primary site of disease.

Cholangiocarcinoma Emerging Therapies
• Surgery with complete resection, Chemotherapy
• TIBSOVO (ivosidenib)
• TRUSELTIQ (infigratinib)
• PEMAZYRE (pemigatinib)
• KEYTRUDA (pembrolizumab)
• Futibatinib (TAS-120) and others

Cholangiocarcinoma Market Dynamics
The Cholangiocarcinoma market dynamics is anticipated to change during the forecast period, owing to the expected launch of new therapies.

Scope of the Cholangiocarcinoma Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Cholangiocarcinoma Market Companies included Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutical, Bayer, Loxo Oncology/Bayer, Zymeworks/BeiGene, TArtificial Intelligenceho Oncology, Merck/GlaxoSmithKline, EisArtificial Intelligence, and several others.
• Cholangiocarcinoma Market Therapies included Copanlisib (BAY 80-6946), E7090, Bintrafusp alfa (GSK4045154; M7824), Futibatinib (TAS-120), ZW25, Larotrectinib, Regorafenib, Derazantinib, Melphalan/HDS, and several others.
• Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma Market Drivers and Barriers

Request Sample of the Cholangiocarcinoma Market Report- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Key Insights
2. Executive Summary of Cholangiocarcinoma (CCA)
3. Competitive Intelligence Analysis for Cholangiocarcinoma (CCA)
4. Cholangiocarcinoma (CCA): Market Overview at a Glance
5. Cholangiocarcinoma (CCA): Disease Background and Overview
6. Patient Journey
7. Cholangiocarcinoma (CCA) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Cholangiocarcinoma (CCA) Unmet Needs
10. Key Endpoints of Cholangiocarcinoma (CCA) Treatment
11. Cholangiocarcinoma (CCA) Marketed Products
12. Cholangiocarcinoma (CCA) Emerging Therapies
13. Cholangiocarcinoma (CCA): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Cholangiocarcinoma (CCA)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. DisclArtificial Intelligencemer
23. About DelveInsight

Do you have any queries related to the report? Ask the analyst- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.